Canaccord analyst Tania Gonsalves lowered the firm’s price target on Quipt Home Medical to C$11 from C$11.25 and reiterates a Buy rating on the shares. With only a few more days to go until the end of the company’s fiscal Q1, the analyst removed $15M in revenue acquired in the quarter to reflect the slowdown in acquisitions. Still, management commented that it has a "very high confidence level" in being able to meet revenue guidance of $180M-$1900M exiting Q1, Gonsalves tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on QIPT:
- Quipt Home Medical Reports Record Fourth Quarter and Fiscal Year 2022 Financial Results Posting Positive Net Income, Revenue Growth of 37% and Adjusted EBITDA Growth of 37%
- Quipt Home Medical reports Q4 EPS 5c vs. (4c) a year ago
- Quipt Home Medical Announces Date and Time for Q4 and Full Year Fiscal 2022 Conference Call and Audio Webcast